These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24581)

  • 21. Kinetics of activation of the first component of complement (C1) by IgG oligomers.
    Tschopp J
    Mol Immunol; 1982 May; 19(5):651-7. PubMed ID: 6287242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of immune complexes. The use of radioimmunoassays with Clq and monoclonal rheumatoid factor.
    Gabriel A; Agnello V
    J Clin Invest; 1977 May; 59(5):990-1001. PubMed ID: 323292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein A from Staphylococcus aureus. The effect of iodination on the reactivity with immunoglobulin G.
    Sjöholm I; Sjödin T
    Eur J Biochem; 1974 Sep; 47(3):491-8. PubMed ID: 4215655
    [No Abstract]   [Full Text] [Related]  

  • 24. Activation of the first component of human complement (C1) by antibody-antigen aggregates.
    Dodds AW; Sim RB; Porter RR; Kerr MA
    Biochem J; 1978 Nov; 175(2):383-90. PubMed ID: 743203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating immune complexes detected by 125I-Clq deviation test in sera of cancer patients.
    Teshima H; Wanebo H; Pinsky C; Day NK
    J Clin Invest; 1977 Jun; 59(6):1134-42. PubMed ID: 325016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Purification and characterization of the 1q subcomponent of canine complement and its use in the 125I-C1q binding assay for detection of immune complexes.
    Wu CC; Bey RF; Loken KI
    Am J Vet Res; 1988 Jun; 49(6):865-9. PubMed ID: 3135770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of the in vitro addition of IgG for therapeutic use to cryoglobulinemic sera].
    Corvetta A; Spaeth PJ
    Recenti Prog Med; 1985 Mar; 76(3):149-51. PubMed ID: 4012018
    [No Abstract]   [Full Text] [Related]  

  • 28. Purification of the subunit Clq from the first component of equine complement.
    McDonald TL; Burger D
    Immunology; 1979 Jul; 37(3):517-27. PubMed ID: 91570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studies on human plasma C1 inactivator-enzyme interactions. II. Structural features of an abnormal C1 inactivator from a kindred with hereditary angioneurotic edema.
    Harpel PC; Hugli TE; Cooper NR
    J Clin Invest; 1975 Mar; 55(3):605-11. PubMed ID: 123252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isolation, by partial pepsin digestion, of the three collagen-like regions present in subcomponent Clq of the first component of human complement.
    Reid KB
    Biochem J; 1976 Apr; 155(1):5-17. PubMed ID: 7240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measles infection. Involvement of the complement system.
    Charlesworth JA; Pussell BA; Roy LP; Robertson MR; Beveridge J
    Clin Exp Immunol; 1976 Jun; 24(3):401-6. PubMed ID: 939047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.
    Gadd KJ; Reid KB
    Biochem J; 1981 May; 195(2):471-80. PubMed ID: 7316962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence against the presence of circulating immune complexes in chronic inflammatory bowel disease.
    Soltis RD; Hasz D; Morris MJ; Wilson ID
    Gastroenterology; 1979 Jun; 76(6):1380-5. PubMed ID: 155547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functionally active C1 on the surface of human peripheral lymphocytes: its role in the complement-mediated inhibition of the Fc receptor of B lymphocytes.
    Füst G; Erdei A; Sármay G; Medgyesi GA; Gergely J
    Clin Immunol Immunopathol; 1976 May; 5(3):377-87. PubMed ID: 776475
    [No Abstract]   [Full Text] [Related]  

  • 35. A comparison of I125 Clq binding, Raji cell binding, and lymphocytotoxic activity in multiple sclerosis.
    Schocket AL; Carr RI; Hardtke MA
    Clin Immunol Immunopathol; 1980 Nov; 17(3):477-81. PubMed ID: 7428189
    [No Abstract]   [Full Text] [Related]  

  • 36. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.
    Harpel PC; Cooper NR
    J Clin Invest; 1975 Mar; 55(3):593-604. PubMed ID: 123251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurements of humoral immunity during treatment with levamisole in rheumatoid arthritis--a review.
    Vischer TL
    J Rheumatol Suppl; 1978; 4():49-53. PubMed ID: 282446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C1 inhibitor-dependent dissociation of human complement component C1 bound to immune complexes.
    Sim RB; Arlaud GJ; Colomb MG
    Biochem J; 1979 Jun; 179(3):449-57. PubMed ID: 475762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus.
    Zubler RH; Lange G; Lambert PH; Miescher PA
    J Immunol; 1976 Jan; 116(1):232-5. PubMed ID: 1245740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Circulating immune complexes and necrotizing vasculitis].
    Tappeiner G; Wolff K
    Hautarzt; 1979 Dec; 30(12):628-33. PubMed ID: 398359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.